441 related articles for article (PubMed ID: 34729652)
1. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis.
Rathore U; Thakare DR; Patro P; Agarwal V; Sharma A; Misra DP
Clin Rheumatol; 2022 Jan; 41(1):33-44. PubMed ID: 34729652
[TBL] [Abstract][Full Text] [Related]
2. Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors.
Matsumoto K; Suzuki K; Takeshita M; Takeuchi T; Kaneko Y
Front Immunol; 2023; 14():1197342. PubMed ID: 37197652
[TBL] [Abstract][Full Text] [Related]
3. Perspectives of JAK Inhibitors for Large Vessel Vasculitis.
Watanabe R; Hashimoto M
Front Immunol; 2022; 13():881705. PubMed ID: 35432355
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies.
Narváez J; Estrada P; LLop D; Vidal-Montal P; Brugarolas E; Maymó-Paituvi P; Palacios-Olid J; Nolla JM
Semin Arthritis Rheum; 2023 Apr; 59():152166. PubMed ID: 36645992
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.
Loricera J; Tofade T; Prieto-Peña D; Romero-Yuste S; de Miguel E; Riveros-Frutos A; Ferraz-Amaro I; Labrador E; Maiz O; Becerra E; Narváez J; Galíndez-Agirregoikoa E; González-Fernández I; Urruticoechea-Arana A; Ramos-Calvo Á; López-Gutiérrez F; Castañeda S; Unizony S; Blanco R
Arthritis Res Ther; 2024 Jun; 26(1):116. PubMed ID: 38840219
[TBL] [Abstract][Full Text] [Related]
6. Comparing treatment options for large vessel vasculitis.
Macaluso F; Marvisi C; Castrignanò P; Pipitone N; Salvarani C
Expert Rev Clin Immunol; 2022 Aug; 18(8):793-805. PubMed ID: 35714219
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the diagnosis and therapy of large vessel vasculitis.
Keser G; Atagunduz P; Soy M
Pol Arch Intern Med; 2022 Jun; 132(6):. PubMed ID: 35699647
[TBL] [Abstract][Full Text] [Related]
9. A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis.
Misra DP; Sharma A; Kadhiravan T; Negi VS
Autoimmun Rev; 2017 Feb; 16(2):179-191. PubMed ID: 27988436
[TBL] [Abstract][Full Text] [Related]
10. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
Hellmich B; Agueda A; Monti S; Buttgereit F; de Boysson H; Brouwer E; Cassie R; Cid MC; Dasgupta B; Dejaco C; Hatemi G; Hollinger N; Mahr A; Mollan SP; Mukhtyar C; Ponte C; Salvarani C; Sivakumar R; Tian X; Tomasson G; Turesson C; Schmidt W; Villiger PM; Watts R; Young C; Luqmani RA
Ann Rheum Dis; 2020 Jan; 79(1):19-30. PubMed ID: 31270110
[TBL] [Abstract][Full Text] [Related]
11. Arterial wall fibrosis in Takayasu arteritis and its potential for therapeutic modulation.
Misra DP; Singh K; Sharma A; Agarwal V
Front Immunol; 2023; 14():1174249. PubMed ID: 37256147
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden.
Eriksson P; Skoglund O; Hemgren C; Sjöwall C
Front Immunol; 2023; 14():1187584. PubMed ID: 37304255
[TBL] [Abstract][Full Text] [Related]
13. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.
Monti S; Águeda AF; Luqmani RA; Buttgereit F; Cid M; Dejaco C; Mahr A; Ponte C; Salvarani C; Schmidt W; Hellmich B
RMD Open; 2019; 5(2):e001003. PubMed ID: 31673411
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
15. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.
Welzel T; Winskill C; Zhang N; Woerner A; Pfister M
Pediatr Rheumatol Online J; 2021 Mar; 19(1):46. PubMed ID: 33766063
[TBL] [Abstract][Full Text] [Related]
16. Advances and challenges in management of large vessel vasculitis.
Chu CQ
Rheumatol Immunol Res; 2023 Dec; 4(4):188-195. PubMed ID: 38125643
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis.
Misra DP; Rathore U; Patro P; Agarwal V; Sharma A
Clin Rheumatol; 2021 Nov; 40(11):4391-4416. PubMed ID: 33932173
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study.
Saito S; Okuyama A; Okada Y; Shibata A; Sakai R; Kurasawa T; Kondo T; Takei H; Amano K
Rheumatology (Oxford); 2020 Jul; 59(7):1617-1621. PubMed ID: 31665468
[TBL] [Abstract][Full Text] [Related]
19. Biotherapies in large vessel vasculitis.
Ferfar Y; Mirault T; Desbois AC; Comarmond C; Messas E; Savey L; Domont F; Cacoub P; Saadoun D
Autoimmun Rev; 2016 Jun; 15(6):544-51. PubMed ID: 26883459
[TBL] [Abstract][Full Text] [Related]
20. Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis.
Banerjee S; Quinn KA; Gribbons KB; Rosenblum JS; Civelek AC; Novakovich E; Merkel PA; Ahlman MA; Grayson PC
J Rheumatol; 2020 Jan; 47(1):99-107. PubMed ID: 30877209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
